Study of an anti-TREM-1 drug in a gut model
Part of Digestive system clinical trials.
This trial tests a new drug that blocks a protein called TREM-1, which may help reduce inflammation in the gut. It uses tissue samples from people with active ulcerative colitis or Crohn's disease to see if the drug is effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You have ulcerative colitis or Crohn's disease that is currently active
- You are willing and able to sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This study follows adults with Crohn’s disease or ulcerative colitis when their treatment is changed. It collects health information and samples to better understand how treatment changes affect people over time.
This study tests whether combining a specific diet with biologic medicines can reduce active inflammation and symptoms of Crohn’s disease. It may help people who still have active disease in the bowel despite prior care.
This trial tests a new medicine (TQH3906) for people with moderate to severe ulcerative colitis or Crohn's disease that hasn't improved with other treatments. The goal is to see if it can help control inflammation in the gut.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.